This adaptive resistance mechanism can be managed by the combination of TCB with anti-PD-L1 (or anti-PD-1) blocking antibodies translating into more efficacious anti-tumor activity and prolonged control of the tumor outgrowth. This evidence concerns the gene CD274 and neoplasm.